These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 18367975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M, Mir M, Marin M, Hurtado S, Estadella C, Gurí X, Rap O, Moral R, Puig JM, Lloveras J.
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [Abstract] [Full Text] [Related]

  • 5. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [Abstract] [Full Text] [Related]

  • 6. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C, Lorenzin D, Rossetto A, Faraci MG, Nicolini D, Garelli P, Bresadola V, Toniutto P, Soardo G, Baroni GS, Adani GL, Risaliti A, Baccarani U.
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y, Hama K, Katayama H, Soga A, Toraishi T, Yokoyama T, Kihara Y, Jojima Y, Konno O, Iwamoto H, Takeuchi H, Hirano T, Shimazu M.
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [Abstract] [Full Text] [Related]

  • 8. Three-month experience with tacrolimus once-daily regimen in stable renal allografts.
    Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E.
    Transplant Proc; 2009 Jan; 41(6):2323-5. PubMed ID: 19715908
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A, Poli L, Nofroni I, Bachetoni A, Tinti F, Umbro I, Barile M, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S, Fujita T, Yoneyama T, Yoneyama T, Koie T, Hashimoto Y, Saitoh H, Funyu T, Narumi S, Ohyama C.
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [Abstract] [Full Text] [Related]

  • 13. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
    de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y.
    Transplantation; 2010 Sep 15; 90(5):523-9. PubMed ID: 20592652
    [Abstract] [Full Text] [Related]

  • 14. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE, Tett SE.
    Clin Pharmacokinet; 2015 Oct 15; 54(10):993-1025. PubMed ID: 26038096
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A, Tinti F, Poli L, Bachetoni A, Umbro I, Nofroni I, Lai Q, Pretagostini R, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2011 May 15; 43(4):1024-7. PubMed ID: 21620042
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F, Debord J, Undre N, Rousseau A, Marquet P.
    Ther Drug Monit; 2010 Apr 15; 32(2):129-35. PubMed ID: 20110850
    [Abstract] [Full Text] [Related]

  • 17. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR, Eckhoff DE, Washburn WK, Teperman LW.
    Liver Transpl; 2014 May 15; 20(5):564-75. PubMed ID: 24493215
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen.
    Meçule A, Tinti F, Bachetoni A, Poli L, D'Alessandro M, Alessandri C, Umbro I, Nofroni I, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2011 May 15; 43(4):1017-9. PubMed ID: 21620040
    [Abstract] [Full Text] [Related]

  • 19. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients.
    Wu MJ, Cheng CY, Chen CH, Wu WP, Cheng CH, Yu DM, Chuang YW, Shu KH.
    Transplantation; 2011 Sep 27; 92(6):648-52. PubMed ID: 21912349
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.